Please login first
Jean Guillon   Professor  Senior Scientist or Principal Investigator 
Timeline See timeline
Jean Guillon published an article in January 2019.
Research Keywords & Expertise
0 A
0 Leukemia
0 Synthesis
0 Protein
0 µm
Top co-authors See all
Jean-Louis Mergny

251 shared publications

ARNA Laboratory, IECB, Inserm U1212, CNRS UMR 5320, Université de Bordeaux, Bordeaux, France

Holger Gohlke

189 shared publications

Heinrich-Heine-Universität Düsseldorf, Germany

Susan Costantini

146 shared publications

Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Tumori-IRCSS-Fondazione G. Pascale, Naples, Italy

Valérie Gabelica

143 shared publications

Laboratoire Acides Nucléiques: Régulations Naturelle et Artificielle, Université de Bordeaux, Inserm & CNRS (ARNA, U1212, UMR5320), IECB, Pessac, France

Joachim Jose

115 shared publications

Institut für Pharmazeutische und Medizinische Chemie, PharmaCampus, Westfälische Wilhelms-Universität Münster, 48149 Münster, Germany

Publication Record
Distribution of Articles published per year 
(2014 - 2019)
Total number of journals
published in
Publications See all
Article 0 Reads 1 Citation Peptide-Based Drug-Delivery Systems in Biotechnological Applications: Recent Advances and Perspectives Diego Tesauro, Antonella Accardo, Carlo Diaferia, Vittoria M... Published: 19 January 2019
Molecules, doi: 10.3390/molecules24020351
DOI See at publisher website PubMed View at PubMed ABS Show/hide abstract
Peptides of natural and synthetic sources are compounds operating in a wide range of biological interactions. They play a key role in biotechnological applications as both therapeutic and diagnostic tools. They are easily synthesized thanks to solid-phase peptide devices where the amino acid sequence can be exactly selected at molecular levels, by tuning the basic units. Recently, peptides achieved resounding success in drug delivery and in nanomedicine smart applications. These applications are the most significant challenge of recent decades: they can selectively deliver drugs to only pathological tissues whilst saving the other districts of the body. This specific feature allows a reduction in the drug side effects and increases the drug efficacy. In this context, peptide-based aggregates present many advantages, including biocompatibility, high drug loading capacities, chemical diversity, specific targeting, and stimuli responsive drug delivery. A dual behavior is observed: on the one hand they can fulfill a structural and bioactive role. In this review, we focus on the design and the characterization of drug delivery systems using peptide-based carriers; moreover, we will also highlight the peptide ability to self-assemble and to actively address nanosystems toward specific targets.
Article 2 Reads 0 Citations Crystal structure and identification of a pyrimido[6,1-b][1,3]oxazin-6-one derivative from the reaction of acrolein with... Jean Guillon, Sandra Rubio, Solène Savrimoutou, François Hal... Published: 01 November 2018
Comptes Rendus Chimie, doi: 10.1016/j.crci.2018.09.013
DOI See at publisher website ABS Show/hide abstract
The X-ray crystal structure of 2-(4,5-dihydro-5-phenoxymethyl-1,3-oxazol-2-ylamino)-7-(2-hydroxy-3-phenoxypropyl)hexahydro-2H,6H-pyrimido[6,1-b][1,3]oxazin-6-one (1), a structure of adduct formed by the reaction of 5-(phenoxymethyl)-2-amino-2-oxazoline and acrolein, has been established. The present work deals with the structural identification of the adduct 1 and presents a plausible mechanism for its formation. It crystallizes in the monoclinic space group P21/c with cell parameters a = 21.3337 (10) Å, b = 11.3712 (7) Å, c = 10.4936 (7) Å, β = 103.041 (3), V = 2480.0 (3) Å3, Z = 4. C26H32N4O6, Dc = 1.330 g/cm3, μ (Cu Kα) = 1.5418 Å, S = 1.188, F (000) = 1056, R = 0.0501, and wR = 0.1584. La structure complète de la 2-(4,5-dihydro-5-phénoxymethyl-1,3-oxazol-2-ylamino)-7-(2-hydroxy-3-phénoxypropyl)hexahydro-2H,6H-pyrimido[6,1-b][1,3]oxazin-6-one 1, une structure d'adduit formée lors de la réaction de la 5-(phénoxyméthyl)-2-amino-2-oxazoline et de l'acroléine, a été établie sans équivoque par une analyse cristallographique aux rayons X. Le présent travail porte sur l'identification structurale de l'adduit 1 et présente un mécanisme plausible pour sa formation. La molécule cristallise dans le système monoclinique, dans le groupe spatial P21/c avec a = 21.3337 (10) Å, b = 11.3712 (7) Å, c = 10.4936 (7) Å, β = 103.041 (3), V = 2480.0 (3) Å3, Z = 4. C26H32N4O6, Dc = 1.330 g/cm3, μ (Cu Kα) = 1.5418 Å, S = 1.188, F (000) = 1056, R = 0.0501 et wR = 0.1584.
Article 4 Reads 0 Citations 1-Methyl-3-{4-[(4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl)benzyl]}-2-phenylindole Jean Guillon, Solène Savrimoutou, Sandra Rubio, Vanessa Desp... Published: 04 October 2018
Molbank, doi: 10.3390/m1023
DOI See at publisher website ABS Show/hide abstract
The 1-methyl-3-{4-[(4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl)benzyl]}-2-phenylindole compound has been successfully synthesized via a multistep pathway starting from 2-phenylindole. Structure characterization of this new indole derivative was done by FTIR, 1H-NMR, 13C-NMR, and HRMS spectral analysis. The title compound showed high cytotoxic potential against five leukemia cell lines (K562, HL60, U937, U266, and Jurkat cell lines).
Article 0 Reads 0 Citations Synthesis, Crystal Structure and Anti-leukemic Activity of 4-{4-[(4-(2-Oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-... Jean Guillon, Stéphane Moreau, Vanessa Desplat, Marian Vince... Published: 17 September 2018
Journal of Chemical Crystallography, doi: 10.1007/s10870-018-0734-2
DOI See at publisher website
Article 0 Reads 1 Citation Design, synthesis, and antiprotozoal evaluation of new 2,9-bis[(substituted-aminomethyl)phenyl]-1,10-phenanthroline deri... Jean Guillon, Anita Cohen, Rabindra Nath Das, Clotilde Boudo... Published: 17 January 2018
Chemical Biology & Drug Design, doi: 10.1111/cbdd.13164
DOI See at publisher website PubMed View at PubMed
Article 0 Reads 2 Citations Design, Synthesis and Biological Evaluation of New Substituted Diquinolinyl-Pyridine Ligands as Anticancer Agents by Tar... Rabindra Nath Das, Edith Chevret, Vanessa Desplat, Sandra Ru... Published: 30 December 2017
Molecules, doi: 10.3390/molecules23010081
DOI See at publisher website PubMed View at PubMed ABS Show/hide abstract
G-quadruplexes (G4) are stacked non-canonical nucleic acid structures found in specific G-rich DNA or RNA sequences in the human genome. G4 structures are liable for various biological functions; transcription, translation, cell aging as well as diseases such as cancer. These structures are therefore considered as important targets for the development of anticancer agents. Small organic heterocyclic molecules are well known to target and stabilize G4 structures. In this article, we have designed and synthesized 2,6-di-(4-carbamoyl-2-quinolyl)pyridine derivatives and their ability to stabilize G4-structures have been determined through the FRET melting assay. It has been established that these ligands are selective for G4 over duplexes and show a preference for the parallel conformation. Next, telomerase inhibition ability has been assessed using three cell lines (K562, MyLa and MV-4-11) and telomerase activity is no longer detected at 0.1 μM concentration for the most potent ligand 1c. The most promising G4 ligands were also tested for antiproliferative activity against the two human myeloid leukaemia cell lines, HL60 and K562.